Clinical Research Directory

Inclusion Criteria: * Adults aged 21-75 years (male or female) * Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI) * Wheelchair user for community mobility * Injury level of tetraplegia (cervical level) or paraplegia (all levels) * SCI-specific obesity indicated by waist circumference ≥94 cm * Resting heart rate \>45 bpm based on 10 measurements over 10 minutes * Without clinically significant cardiovascular abnormalities as indicated by 12-lead ECG * Tolerable bowel routine indicated by a score of \<10 on the International SCI Bowel Function Data Set (ISCI-BDS) * Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg/dL, (3) dyslipidemia: high triglycerides ≥150 mg/dL or low HDL cholesterol \<40 mg/dL for men and \<50 mg/dL for women, (4) C-reactive protein (CRP) levels \>1 mg/dL * Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures * Willingness to comply with all study procedures and availability for the duration of the study * Provision of signed and dated informed consent form Exclusion Criteria: * Diagnosis of neurological injury or condition other than SCI * Progressive condition that would be expected to change neurological status * Signs and symptoms of cardiovascular disease or cardiac arrhythmias * Resting heart rate \<45 bpm * Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction * Severe concurrent medical disease, condition, or illness judged to be contraindicated by the site physician * Psychopathology documented in the medical record or history that may conflict with study objectives * Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study * Active cancer or currently in treatment for cancer * Triglyceride levels ≥400 mg/dL * Chronic use of medications with known or probable interactions with galantamine * Enrolled in another research study that is likely to interfere with conduct or results of the current study * Any other reason the site physician feels that participation is contraindicated